<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">856</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2017-16-1-61-69</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">ANTI-TUMOR EFFECT OF CPDA ENANTIOMERS IN VITRO IN THE MODEL OF ACUTE LYMPHOBLASTIC LEUKEMIA</article-title><trans-title-group xml:lang="ru"><trans-title>ПРОТИВООПУХОЛЕВЫЙ ЭФФЕКТ ЭНАНТИОМЕРОВ CPDA IN VITRO НА МОДЕЛИ ОСТРОГО ЛИМФОБЛАСТНОГО ЛЕЙКОЗА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Savinkova</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Савинкова</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tilova</surname><given-names>L. R.</given-names></name><name xml:lang="ru"><surname>Тилова</surname><given-names>Л. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Borisova</surname><given-names>O. I.</given-names></name><name xml:lang="ru"><surname>Борисова</surname><given-names>О. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zhidkova</surname><given-names>E. M.</given-names></name><name xml:lang="ru"><surname>Жидкова</surname><given-names>Е. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kuzin</surname><given-names>K. A.</given-names></name><name xml:lang="ru"><surname>Кузин</surname><given-names>К. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kirsanov</surname><given-names>K. I.</given-names></name><name xml:lang="ru"><surname>Кирсанов</surname><given-names>К. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Belitsky</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Белицкий</surname><given-names>Г. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Budunova</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Будунова</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yakubovskaya</surname><given-names>M. G.</given-names></name><name xml:lang="ru"><surname>Якубовская</surname><given-names>М. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lesovaya</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Лесовая</surname><given-names>Екатерина Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>lesovenok@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin Russian Cancer Research Center</institution></aff><aff><institution xml:lang="ru">ФГБУ«Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Moscow Technological University</institution></aff><aff><institution xml:lang="ru">Московский технологический университет</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Northwestern University</institution></aff><aff><institution xml:lang="ru">Северо-Западный университет</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Ryazan State Medical University named after academician I.P. Pavlov</institution></aff><aff><institution xml:lang="ru">Рязанский государственный медицинский университет им. И.П. Павлова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-03-30" publication-format="electronic"><day>30</day><month>03</month><year>2017</year></pub-date><volume>16</volume><issue>1</issue><fpage>61</fpage><lpage>69</lpage><history><date date-type="received" iso-8601-date="2018-04-10"><day>10</day><month>04</month><year>2018</year></date></history><permissions/><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/856">https://bioterapevt.abvpress.ru/jour/article/view/856</self-uri><abstract xml:lang="en"><p>Introduction. Glucocorticoids are the important component of combined chemotherapy of blood cancer. Therapeutic effects of glucocorticoids is realized via activation of glucocorticoid receptor transrepression, the development of side effects is associated with transactivation. We demonstrated earlier that compound belonging the class of selective glucocorticoid receptor agonists, CpdA, selectively induced transrepression in blood cancer cells. CpdA represents a mixture of two enantiomers, which can differ in interaction with the receptor. Aim. The main aim of present study was to synthesize CpdA enantiomers and to evaluate their biological properties. Materials and methods. Synthesis was carried out based on Sharpless dihydroxylation; anti-tumor activity in vitro was evaluated by antiproliferative and pro-apoptotic effects. Ligand properties were estimated by PCR-analysis of glucocorticoid- and NF-kB-dependent genes expression. Results and conclusions. We demonstrated that CpdA enantiomers revealed anti-tumor activity in vitro and did not induce transactivation. Moreover, S-enantiomer of CpdA in the most tests demonstrated more pronounced activity and is more perspective molecule for future studies in vivo.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="ru"><kwd>глюкокортикоидный рецептор</kwd><kwd>энантиомеры</kwd><kwd>гемобластозы</kwd><kwd>транс-активация</kwd><kwd>транс-репрессия</kwd><kwd>противоопухолевая активность</kwd><kwd>glucocorticoid receptor</kwd><kwd>enantiomers</kwd><kwd>hemoblastosis</kwd><kwd>transactivation</kwd><kwd>transrepression</kwd><kwd>anti-tumor activity</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Басов П.В. Влияние глюкокортикоидных гормонов на Т-лимфоциты у больных туберкулезом легких. Проблемы туберкулеза 1990; 1: 30-3.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Витовская О.П. Медикаментозно индуцированная глаукома. Офтальмологические ведомости 2014; 7(3): 58-62.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Иванова А.А. Механизмы антилейкемического действия и возможные пути развития резистентности при использовании глюкокортикоидов в терапии острых лейкозов (обзор литературы). Гематология и трансфузиология 2000; 45(2): 12-5.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Спичак И.И., Богачева М.В., Билялутдинова Д.И. и др. Частота стероидного диабета на программной полихиомиотерапии у детей с лимфобластным лейкозом. Педиатрический вестник Южного Урала 2014; 1-2: 30-3.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Страчунский Л.С., Козлов С.Н. Глюкокортикоидные препараты. Методическое пособие. Смоленск, 1997.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Cutolo M. Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD open 2016; 2(1): 1 -10. DOI: 10.1136/rmdopen-2015-000203. PMID: 27042335.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Klaustermeyer W.B., Choi S.H. A perspective on systemic corticosteroid therapy in severe bronchial asthma in adulds. Allergy Asthma Proc 2016; 37(3): 192-8.DOI: 10.2500/aap.2016.37.3941. PMID: 27178888.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Топорова И.Ю., Паровичникова Е.Н., Клясова Г.А. и др. Частота развития и структура инфекционных осложнений, возникающих у больных с гемобластозами на различных этапах программной химиотерапии. Гематология и трансфузиология (приложение) 2012; 54.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lekva T., Bollerslev T.J., Kristo C. et al. The glucocorticoid-induced leucine zipper gene (GILZ) expression decreases after successful treatment of patients with endogenous Cushing’s syndrome and may play a role in glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 2010; V(1): 246-55. DOI: 10.1210/jc.2009-0595. PMID: 19875485.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Thompson E.B., Harmon J.M. Glucocorticoid receptors and glucocorticoid resistance in human leukemia in vivo and in vitro. Adv Exp Med Biol 1986; 196: 111-27. DOI: 10.1007/978-1 -4684-5101-6_8. PMID: 3521219.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Лесовая Е.А., Емельянов А.Ю., Кирсанов К.И. и др. Противоопухолевое действие нестероидного лиганда глюкокортикоидного рецептора, CpdA, на клетки линий Т-клеточного лейкоза. Биохимия (Москва) 2011; 76(11): 1242-52.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Polman J.A., de Kloet E.R., Datson N.A. Two populations of glucocorticoid receptor-binding sites in the male rat hippocampal genome. Endocrinology 2013; 154(5): 1832-44. DOI: 10.1210/en.2012-2187. PMID: 23525215.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Ray A., Prefontaine K.E. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91(2): 752-6. PMID: 8290595.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Хаитов Р.М., Ильина Н.И. Аллергология и иммунология. Национальное руководство. М.: ГОЭТАР-Медиа, 2012. 633 с.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Hudson W.H., Youn C., Ortlund E.A. The structural basis of direct glucocorticoid-mediated transrepression. Nat Struct Mol Biol 2013; 20(1): 53-8. DOI: 10.1038/nsmb.2456. PMID: 23222642.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Surjit M., Ganti K.P., Mukherji A. et al. Widespread negative response elements mediate direct repression by agonist-leganded glucocorticoid receptor. Cell 2011; 145(2): 224-41. DOI: 10.1016/j.cell.2011.03.027. PMID: 21496643.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bosscher de K., Haegeman G., Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 2010; 10(4): 497-504. DOI: 10.1016/j.coph.2010.04.007. PMID: 20493772.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Lesovaya E., Yemelyanov A., Swart A.C. et. al. Discovery of Compound A - a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity. Oncotarget 2015; 6(31): 30730-44. DOI: 10.18632/oncotarget.5078. PMID: 26436695.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Sharpless K.B., Amberg W., Bennani Y.L. et al. The osmium-catalyzed asymmetric dihydroxylation: a new ligand class and process improvement. JOC 1992; 57(10): 2768-71. DOI: 10.1021/jo00036a003.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Antakly T., Eisen H.J. Immunocytochemical localization of the glucocorticoid receptor in steroidsensitive and -resistant human leukemic cells. Cancer Res 1990; 50(4): 1337-45. PMID: 2404592.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Foley G.E., Lazarus H., Farber S. et al. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965; 18: 522-9. PMID: 14278051.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Norman M.R. Thompson E.B. Characterization of a glucocorticoid-sensitive human lymphoid cell line. Cancer Res 1977; 37(10): 3785-91. PMID: 269011.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Thompson E.B., Medh R.D., Zhou F. et al. Glucocorticoids, oxysterols, and cAMP with glucocorticoids each cause apoptosis of CEM cells and suppress c-myc. J Steroid Biochem Mol Biol 1999; 69(1-6): 453-61. PMID: 10419025.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Kubista M., Andrade J.M., Bengtsson M. et al. The real-time polymerase chain reaction. Molecular Aspects of Medicine 2006; 27: 95-125. DOI: 10.1016/j. mam. 2005.12.007. PMID: 16460794.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Lesovaya E., Yemelyanov A., Kirsanov K. et al. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies. Cell Cycle 2013; 12(1): 133-44. DOI: 10.4161/cc.23048. PMID: 23255118.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Yemelyanov A., Czwornog J., Gera L. et al. Novel steroid receptor phytomodulator compound A inhibits growth and survival of prostate cancer cells. Cancer Res 2008; 68(12): 4763-73. DOI: 10.1158/0008-5472.CAN-07-6104. PMID: 18559523.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Adcock I.M. Molecular mechanisms of glucocorticosteroid actions. Pulm Pharmacol Ther 2000; 13(3): 115-26. DOI: 10.1006/pupt. 2000.0243. PMID: 10873549.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Chauhan D., Auclair D., Robinson E.K. et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002; 21(9): 1346-58. DOI: 10.1038/sj.onc.1205205. PMID: 11857078.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Bruscoli S., Donato V., Velardy E. et al. Glucocorticoid-induced leucine zipper (GILZ) and long GILZ inhibit myogenic differentiation and mediate anti-myogenic effects of glucocorticoids. J Biol Chem 2010; 285(14): 10385-96. DOI: 10.1074/jbc.M109.070136. PMID: 20124407. PMCID: PMC2856245.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Kochel I., Strzadala L. FK506-binding proteins in the regulation of transcription factors activity in T cells. Postepy Hig Med Dosw 2004; 58: 118-27. PMID: 15077060.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Shipp L.E., Lee J.V., Yu C.Y. et al. Transcriptional regulation of human dual specificity protein phosphatase 1(DUSP1) gene by glucocorticoids. PLoS One 2010; 5(10): 13754. DOI: 10.1371/journal.pone.0013754. PMID: 21060794.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Tchen C.R., Martins J.R., Paktiawal N. et al. Glucocorticoid regulation of mouse and human dual specificity phosphatase 1(DUSP1) genes: unusual cis-acting elements and unexpected evolutionary divergence. J Biol Chem 2010; 285(4): 2642-52. DOI: 10.1074/jbc.M109.037309. PMID: 19940143.</mixed-citation></ref></ref-list></back></article>
